Playing Well With Others | GenomeWeb

Despite the criticism Myriad Genetics receives for its business practices regarding BRCA testing, the company has stayed on message about two things. One, that its exclusive licenses and patents on BRCA 1 and BRCA 2 mutations, which essentially give it a monopoly over the BRCA testing market for hereditary breast and ovarian cancer, is good for business. And two, that the enforcement of its IP rights hasn't been harmful for patients or for researchers looking to develop better tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.